(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 March 2023 (16.03.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/036862 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 38/26* (2006.01)
A61K 9/08 (2006.01) *A61K 47/18* (2017.01)
A61K 9/19 (2006.01) *A61K 47/26* (2006.01)

(21) International Application Number:
PCT/EP2022/074961

(22) International Filing Date:
08 September 2022 (08.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21196169.3 10 September 2021 (10.09.2021) EP

(71) Applicant: **ZEALAND PHARMA A/S** [DK/DK]; Sydmarken 11, DK-2860 Søborg (DK).

(72) Inventors: **MØLLER, Eva Horn**; Sydmarken 11, DK-2860 Søborg (DK). **LUNDQVIST, Joakim**; Sydmarken 11, DK-2860 Søborg (DK).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol, Gloucestershire BS1 6BX (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: PROCESS FOR FORMULATING COMPOSITIONS COMPRISING GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES

(57) Abstract: Processes for producing a stable liquid pharmaceutical formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, and in particular to processes for producing formulations that comprise ZP1848 (glepaglutide) or ZP1846 (elsiglutide) based on one- pot formulation.

WO 2023/036862 A1